Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NAAA | Q02083 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31500526 | 0.95 | NAAA (0.52) | HTTTSHRSMN1; SMN2NAAAHPGD | |
| SCHEMBL9967355 | 0.94 | NAAA (0.55) | HTTTSHRSMN1; SMN2NAAAHPGD | |
| SCHEMBL8358319 | 0.85 | EGLN2 (0.61) | HTTTSHRSMN1; SMN2NAAAHPGD | |
| SCHEMBL10709742 | 0.84 | EGLN2 (0.49) | HTTTSHRRAB9ANPC1L3MBTL1 | |
| SCHEMBL13310736 | 0.84 | PARP1 (0.48) | HTTL3MBTL1KMT2A | |
| SCHEMBL30131475 | 0.84 | HPGD (0.60) | HTTTSHRSMN1; SMN2NAAAHPGD | |
| Hydrochloric Acid SCHEMBL10707149 | 0.82 | CHEK1 (0.47) | TSHRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL9206936 | 0.81 | HTT (0.56) | HTTTSHRSMN1; SMN2NAAAHPGD | |
| SCHEMBL1423557 | 0.81 | EGLN2 (0.60) | HTTTSHRSMN1; SMN2NAAAHPGD | |
| SCHEMBL10244761 | 0.80 | SMN1; SMN2 (0.49) | HTTTSHRSMN1; SMN2NAAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290350-A | Heteroaryl and bisheteroaryl derivatives for the treatment of iron death-related disorders | 协同医药发展有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-113631535-B | Heteroaryl and bisheteroaryl derivatives for the treatment of iron death-related disorders | 协同医药发展有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-113631535-A | Heteroaryl and bis-heterocyclic aryl derivatives for the treatment of disorders associated with iron death | 协同医药发展有限公司 | 2021-11-09 | — | — | CN | disclosed |
| EP-1791842-A1 | PROCESS FOR THE PREPARATION OF 6, 8-SUBSTITUTED `1, 7 NAPHTHPYRIDIN DERIVATIVES BY REACTING THE 8-HALO-`1, 7 NAPHTHPYRIDIN-DERIVATE WITH AN ORGANIC BORONIC ACID DERIVATIVES AND INTERMADIATES OF THIS PROCESS | Novartis AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006031959-A1 | PROCESS FOR THE PREPARATION OF 6, 8-SUBSTITUTED `1, 7 NAPHTHPYRIDIN DERIVATIVES BY REACTING THE 8-HALO-`1, 7 NAPHTHPYRIDIN-DERIVATE WITH AN ORGANIC BORONIC ACID DERIVATIVES AND INTERMADIATES OF THIS PROCESS | NOVARTIS AG (CH) | 2006-03-23 | — | — | WO | disclosed |